3. Network effect estimates and ranking statistics for receipt of pharmacotherapy for symptomatic PDA.

Acetaminophen Mean SUCRA, 0.52; median rank, 3 (95% CrI, 1‐4)
1.66 ( 0.57, 7.10)	Ibuprofen Mean SUCRA, 0.90; median rank, 1 (95% CrI, 1‐3)
1.10 ( 0.40, 4.53)	0.66 ( 0.32, 1.43)	Indomethacin Mean SUCRA, 0.56; median rank, 2 (95% CrI, 1‐3)
0.32 ( 0.13, 1.12)	0.20 ( 0.098, 0.33)	0.30 ( 0.17, 0.43)	Placebo Mean SUCRA, 0.01; median rank, 4 (95% CrI, 3‐4)

The unlabeled data in the boxes are risk ratios (RRs) and 95% credible intervals (CrIs). A RR >1 suggests that the upper left treatment is associated with a higher risk of having the outcome of interest vs the corresponding lower right treatment and the opposite is true for an RR <1. SUCRA, surface under the cumulative ranking curve